Quick Answer
PRECISION BIOSCIENCES INC reported Total Revenue of $34.26 million for fiscal year 2025.
PRECISION BIOSCIENCES INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $34.26M -50.1% |
$68.70M +41.0% |
$48.73M +94.1% |
$25.10M -78.3% |
$115.53M +375.7% |
$24.29M +9.2% |
| Revenue (ASC 606) | $34.26M -50.1% |
$68.70M +41.0% |
$48.73M +94.1% |
$25.10M -78.3% |
$115.53M +375.7% |
$24.29M +9.2% |
| Net Income | -$45.72M -738.0% |
$7.17M +111.7% |
-$61.32M +45.1% |
-$111.64M -264.8% |
-$30.60M +71.9% |
-$109.01M -17.4% |
| Diluted EPS | -$3.56 -442.3% |
$1.04 +106.5% |
-$15.96 +58.1% |
-$38.10 -7226.9% |
-$0.52 | — |
| Total Assets | $154.42M +13.2% |
$136.39M -14.6% |
$159.78M -32.9% |
$238.17M +12.6% |
$211.50M +40.9% |
$150.16M -36.2% |
| Cash and Equivalents | $110.82M +29.0% |
$85.90M -26.4% |
$116.68M -38.5% |
$189.58M +32.0% |
$143.66M +60.0% |
$89.80M -50.4% |
| Long-Term Debt | — | — | — | $22.22M +796.8% |
$2.48M | — |
| Stockholders Equity | $92.25M +63.6% |
$56.39M +199.0% |
$18.86M -68.8% |
$60.43M -33.7% |
$91.17M +105.2% |
$44.42M -67.9% |
| R&D Expense | $54.17M -9.0% |
$59.56M +11.6% |
$53.38M +15.7% |
$46.12M -60.0% |
$115.24M +17.5% |
$98.06M +19.0% |
| Operating Income | -$52.15M -99.3% |
-$26.16M +40.2% |
-$43.74M +29.8% |
-$62.31M -58.2% |
-$39.38M +64.1% |
-$109.83M -25.9% |
| Shares Outstanding | 24.09M +193.7% |
8.20M +97.0% |
4.16M +12.6% |
3.70M -93.9% |
60.90M +15.6% |
52.69M +3.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $13.0K | -97.7% | -27.8% |
| Revenue (ASC 606) | September 30, 2025 | $13.0K | -97.7% | -27.8% |
| Net Income | September 30, 2025 | -$21.77M | -32.6% | +7.4% |
| Diluted EPS | September 30, 2025 | -$1.84 | +18.2% | +13.6% |
| Total Assets | September 30, 2025 | $93.51M | -39.0% | -14.2% |
| Cash and Equivalents | September 30, 2025 | $44.87M | -54.6% | -27.9% |
| Long-Term Debt | March 31, 2023 | $22.27M | +797.3% | +0.2% |
| Stockholders Equity | September 30, 2025 | $16.63M | -74.4% | -51.2% |
| R&D Expense | September 30, 2025 | $13.35M | +2.0% | +4.6% |
| Operating Income | September 30, 2025 | -$20.67M | +2.9% | +5.5% |
| Shares Outstanding | September 30, 2025 | 12.08M | +61.5% | +3.8% |
- PRECISION BIOSCIENCES INC reported Total Revenue of $34.26 million for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed a decrease of -50.1% in Total Revenue compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Revenue (ASC 606) of $34.26 million for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed a decrease of -50.1% in Revenue (ASC 606) compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Net Income of -$45.72 million for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed a decrease of -738.0% in Net Income compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Diluted EPS of $3.56 per share (loss) for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed a decrease of -442.3% in Diluted EPS compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Total Assets of $154.42 million for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed an increase of +13.2% in Total Assets compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Cash and Equivalents of $110.82 million for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed an increase of +29.0% in Cash and Equivalents compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Long-Term Debt of $22.22 million for fiscal year 2022.
- PRECISION BIOSCIENCES INC showed an increase of +796.8% in Long-Term Debt compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Stockholders Equity of $92.25 million for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed an increase of +63.6% in Stockholders Equity compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported R&D Expense of $54.17 million for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed a decrease of -9.0% in R&D Expense compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Operating Income of -$52.15 million for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed a decrease of -99.3% in Operating Income compared to the prior fiscal year.
- PRECISION BIOSCIENCES INC reported Shares Outstanding of 24.09 million shares for fiscal year 2025.
- PRECISION BIOSCIENCES INC showed an increase of +193.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: